- NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT
-
The present invention relates to a novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The novel fused pyrimidine based sulfonamide derivative of the present invention can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.
- -
-
Paragraph 0076; 0077
(2021/07/02)
-
- NOVEL PYRIMIDINE DERIVATIVE HAVING EFFECT OF INHIBITING CANCER CELL GROWTH AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
The present invention provides a novel pyrimidine derivative compound and a salt thereof. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mecha
- -
-
Paragraph 0042-0043
(2020/11/23)
-
- Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same
-
The present invention provides a novel compound represented by chemical formula 1 or a salt thereof, and a pharmaceutical composition for treating lung cancer containing the same. Since the pyrimidine derivative compound represented by the chemical formul
- -
-
Paragraph 0123; 0127-0130
(2020/12/05)
-
- TYK2 INHIBITORS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
- -
-
Paragraph 001342; 001343
(2018/05/15)
-
- TYK2 INHIBITORS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
- -
-
Paragraph 00611; 00612
(2018/04/27)
-
- PYRROLOPYRIMIDINES AS FAK AND ALK INHIBITERS FOR TREATMENT OF CANCERS AND OTHER DISEASES
-
Disclosed are compounds which inhibit the activity of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), compositions containing the compounds, and methods of treating diseases during which FAK and ALK are expressed. The diseases are, for example, cancers.
- -
-
-
- 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS
-
The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.
- -
-
Page/Page column 67
(2012/07/27)
-